Smith & Nephew

SNN · LONDON

$30.83−$0.05 (−0.16%)TodayMarket closed ·
Prev close $30.88

Latest news

  • Press releaseGlobe Newswire

    Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal

  • Press releaseGlobe Newswire

    MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management

  • Press releaseGlobe Newswire

    Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management

  • Press releaseGlobe Newswire

    Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK™ Total Knee System

  • Press releaseGlobe Newswire

    Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026

  • Press releaseACCESS Newswire

    Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds

  • Press releaseACCESS Newswire

    Smith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds

  • Press releaseACCESS Newswire

    Smith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m

  • NewsAvi Kapoor

    Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

  • Press releaseGlobe Newswire

    Smith+Nephew and Imperial College London launch centre to accelerate innovation in surgical robotics

  • Press releaseGlobe Newswire

    Smith+Nephew’s new FLOW FLEXTEND™ COBLATION™ Wand improves access¹* and resection efficiency²** for complex hip procedures vs. fixed-angle options

  • NewsAvi Kapoor

    Powell Industries Posts Downbeat Q3 Results, Joins Clearpoint Neuro, Ichor Holdings And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

  • Press releasePRNewswire

    Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower

  • Press releaseGlobe Newswire

    A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus

  • Press releaseGlobe Newswire

    A Reno Biotech Just Rang the Nasdaq Bell — Here's Why the Whole Regenerative-Medicine Tape Is Worth Watching

  • NewsAvi Kapoor

    Jim Cramer Says Sell Super Micro — Calls A European Chipmaker 'Cheap And Good'

  • NewsAvi Kapoor

    Sterling Infrastructure Posts Better-Than-Expected Earnings, Joins Lemonade, DigitalOcean Holdings, Lattice Semiconductor And Other Big Stocks Moving Higher On Tuesday

  • NewsAvi Kapoor

    Top 2 Health Care Stocks You May Want To Dump In Q3

  • NewsAvi Kapoor

    Why Palantir Technologies Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket

  • Press releaseGlobe Newswire

    Smith+Nephew and Standard Health partner on first Orthopaedic Ambulatory Surgery Centre in the UK

  • Press releaseGlobe Newswire

    Smith+Nephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of Defense

  • NewsLekha Gupta

    Xpeng, Li Auto And Nutanix Are Among Top 12 Large-Cap Gainers Last Week (Feb 24-Feb 28): Are The Others In Your Portfolio?

  • News

    Earnings Scheduled For February 25, 2025

  • NewsAvi Kapoor

    Estée Lauder, Robinhood, eBay And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

  • Press releasePRNewswire

    Cadence Welcomes Bob White to Board of Directors

  • Press releaseBusiness Wire

    InfuSystem Announces Distribution Agreement with Smith+Nephew for Negative Pressure Wound Therapy System and First Shipment of NPWT Systems

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.